On Tuesday, Recursion Pharmaceuticals (RXRX) stock reached a key performance benchmark, with its Relative Strength (RS) Rating rising into the 90-plus percentile with an improvement to 92, a rise from 64 the day before. This unique rating identifies technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks…
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。